GlassScriptPhysician profile
Anibal F Rossel
NPI 1952373631
$15,685.27
in general payments reported to CMS, 2019-2025
36 companies · $2,100 in 2025
The $2,100 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,696 · 2020: $2,222 · 2021: $2,875 · 2022: $2,430 · 2023: $1,761 · 2024: $1,601 · 2025: $2,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,462.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,275.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,370.60 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Paratek Pharmaceuticals, INC. | $1,563.84 | 2020-2025 | Nuzyra, Xhance |
| Lilly USA, LLC | $1,367.70 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Glaxosmithkline, LLC. | $901.12 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $875.05 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $655.14 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amarin Pharma, INC. | $507.14 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $428.92 | 2019-2025 | |
| Esperion Therapeutics, INC. | $407.56 | 2020-2024 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $360.50 | 2019-2024 | Cycloset, Xifaxan |
| Mannkind Corporation | $347.78 | 2019-2023 | Afrezza |
| Astellas Pharma US INC | $304.85 | 2019-2023 | Myrbetriq |
| Merck Sharp & Dohme LLC | $290.47 | 2019-2021 | |
| Amgen INC. | $275.22 | 2019-2025 | Repatha, Otezla, Repatha |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $259.00 | 2021-2024 | Linzess |
| Allergan, INC. | $244.72 | 2019-2020 | |
| Corcept Therapeutics | $193.58 | 2024-2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $185.16 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $159.15 | 2020-2025 | Zoryve |
| Takeda Pharmaceuticals U.S.A., INC. | $140.32 | 2019-2021 | |
| Pfizer INC. | $129.64 | 2020-2025 | |
| Ironwood Pharmaceuticals, INC | $74.52 | 2020-2022 | |
| Dexcom, INC. | $66.24 | 2024-2025 | Dexcom G6 Transmitter |
| Radius Health, INC. | $60.07 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $58.78 | 2019-2020 | |
| Horizon Therapeutics Plc | $23.08 | 2021-2022 | |
| Genentech USA, INC. | $22.30 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $22.20 | 2019 | |
| Shield Therapeutics INC | $20.25 | 2024 | |
| Althera Pharmaceuticals LLC | $19.51 | 2022 | |
| Assertio Therapeutics, INC. | $17.25 | 2020 | |
| Optos, INC. | $17.09 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.10 | 2021 | |
| Scynexis, INC. | $12.95 | 2022 | |
| Avanir Pharmaceuticals, INC. | $12.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anibal Rossel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.